Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
K Shiraki, N Sato, K Sakai, S Matsumoto… - Pharmacology & …, 2022 - Elsevier
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …